Liberum Capital Reaffirms Buy Rating for Reckitt Benckiser Group (RB)

Reckitt Benckiser Group (LON:RB)‘s stock had its “buy” rating reissued by research analysts at Liberum Capital in a research report issued to clients and investors on Friday.

A number of other analysts have also recently weighed in on RB. JPMorgan Chase & Co. set a GBX 7,000 ($91.47) price target on shares of Reckitt Benckiser Group and gave the stock a “buy” rating in a research note on Monday, July 23rd. Cfra set a GBX 7,500 ($98.00) price target on shares of Reckitt Benckiser Group and gave the stock a “buy” rating in a research note on Monday, July 30th. Jefferies Financial Group set a GBX 6,800 ($88.85) price target on shares of Reckitt Benckiser Group and gave the stock a “neutral” rating in a research note on Wednesday, August 1st. UBS Group reiterated a “neutral” rating and set a GBX 6,000 ($78.40) price target on shares of Reckitt Benckiser Group in a research note on Friday, July 27th. Finally, Kepler Capital Markets set a GBX 6,300 ($82.32) price target on shares of Reckitt Benckiser Group and gave the stock a “neutral” rating in a research note on Friday, July 27th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the company’s stock. Reckitt Benckiser Group presently has an average rating of “Hold” and a consensus target price of GBX 7,021.25 ($91.75).

LON RB opened at GBX 6,505 ($85.00) on Friday. Reckitt Benckiser Group has a 12 month low of GBX 5,562 ($72.68) and a 12 month high of GBX 8,110.43 ($105.98).

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

Featured Article: Analyzing a company’s cash flow statement

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply